Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection-Reference-Cited by-同舟云学术

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Published:2014-01-16 Issue:3 Volume:370 Page:211-221
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Sulkowski Mark S.,Gardiner David F.,Rodriguez-Torres Maribel,Reddy K. Rajender,Hassanein Tarek,Jacobson Ira,Lawitz Eric,Lok Anna S.,Hinestrosa Federico,Thuluvath Paul J.,Schwartz Howard,Nelson David R.,Everson Gregory T.,Eley Timothy,Wind-Rotolo Megan,Huang Shu-Pang,Gao Min,Hernandez Dennis,McPhee Fiona,Sherman Diane,Hindes Robert,Symonds William,Pasquinelli Claudio,Grasela Dennis M.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1306218

Cited by 1049 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease;Egyptian Liver Journal;2024-09-09

2. Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C;Clinical and Experimental Medicine;2024-08-08

3. Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time?;World Journal of Transplantation;2024-06-18

4. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

5. Synthesis of Fluorinated Nucleosides/Nucleotides and Their Antiviral Properties;Molecules;2024-05-19